Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes.
BACKGROUND
One of the most striking features of the childhood malignancy neuroblastoma (NB) is its clinical heterogeneity. Although there is a great need for better clinical and biological markers to distinguish between tumours with different severity and to improve treatment, no clear-cut prognostic factors have been found. Also, no major NB tumour suppressor genes have been identified.


METHODS
In this study we performed expression analysis by quantitative real-time PCR (QPCR) on primary NB tumours divided into two groups, of favourable and unfavourable outcome respectively. Candidate genes were selected on basis of lower expression in unfavourable tumour types compared to favourables in our microarray expression analysis. Selected genes were studied in two steps: (1) using TaqMan Low Density Arrays (TLDA) targeting 89 genes on a set of 12 NB tumour samples, and (2) 12 genes were selected from the TLDA analysis for verification using individual TaqMan assays in a new set of 13 NB tumour samples.


RESULTS
By TLDA analysis, 81 out of 87 genes were found to be significantly differentially expressed between groups, of which 14 have previously been reported as having an altered gene expression in NB. In the second verification round, seven out of 12 transcripts showed significantly lower expression in unfavourable NB tumours, ATBF1, CACNA2D3, CNTNAP2, FUSIP1, GNB1, SLC35E2, and TFAP2B. The gene that showed the highest fold change in the TLDA analysis, POU4F2, was investigated for epigenetic changes (CpG methylation) and mutations in order to explore the cause of the differential expression. Moreover, the fragile site gene CNTNAP2 that showed the largest fold change in verification group 2 was investigated for structural aberrations by copy number analysis. However, the analyses of POU4F2 and CNTNAP2 showed no genetic alterations that could explain a lower expression in unfavourable NB tumours.


CONCLUSIONS
Through two steps of verification, seven transcripts were found to significantly discriminate between favourable and unfavourable NB tumours. Four of the transcripts, CACNA2D3, GNB1, SLC35E2, and TFAP2B, have been observed in previous microarray studies, and are in this study independently verified. Our results suggest these transcripts to be markers of malignancy, which could have a potential usefulness in the clinic.
Thorell
Kaisa
K
Department of Clinical Genetics, Gothenburg University, S-405 30 Gothenburg, Sweden. kaisa.thorell@wlab.gu.se
Bergman
Annika
A
Carén
Helena
H
Nilsson
Staffan
S
Kogner
Per
P
Martinsson
Tommy
T
Abel
Frida
F
Nature. 2008 Oct 16;455(7215):930-5
18724359
Oncogene. 2008 Jan 3;27(1):145-54
17637757
Biochem J. 2008 Dec 1;416(2):153-9
18990089
Nature. 2008 Oct 16;455(7215):967-70
18923523
Eur J Cancer. 2002 Jan;38(1):92-8
11750845
Cancer Res. 1971 Dec;31(12):2098-103
5120301
Lancet. 2007 Jun 23;369(9579):2106-20
17586306
BMC Cancer. 2007 May 25;7:89
17531100
Cancer Res. 2006 Jun 15;66(12):6050-62
16778177
J Clin Oncol. 1999 Jul;17(7):2264-79
10561284
Clin Cancer Res. 2006 Sep 1;12(17):5118-28
16951229
Oncogene. 2007 Nov 8;26(51):7267-81
17525748
Cancer. 1987 Jun 1;59(11):1853-9
3567848
Cancer Res. 1995 Dec 1;55(23):5681-6
7585654
J Biol Chem. 2004 May 14;279(20):21617-27
14970234
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
12184808
Curr Opin Pediatr. 2005 Feb;17(1):7-13
15659956
J Clin Oncol. 2009 Jan 10;27(2):298-303
19047290
Genes Chromosomes Cancer. 2007 Oct;46(10):936-49
17647283
BMC Genomics. 2008 Jul 29;9:353
18664255
Dev Biol. 1998 May 15;197(2):155-69
9630743
Nature. 2008 Oct 16;455(7215):975-8
18923525
Nature. 2008 Oct 16;455(7215):971-4
18923524
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3740-5
11891299
Cancer. 2008 Sep 15;113(6):1412-22
18671248
Int J Oncol. 2009 Mar;34(3):697-705
19212675
Nucleic Acids Res. 2005 Jan 13;33(1):e9
15653630
Carcinogenesis. 2004 Sep;25(9):1599-609
15090470
J Neurosci. 2001 Oct 1;21(19):7568-75
11567047
Nat Med. 2001 Jun;7(6):673-9
11385503
Gene. 2003 Feb 27;305(2):217-23
12609742
Gastroenterology. 2008 Aug;135(2):580-90
18588891
Nucleic Acids Res. 2006;34(22):6640-52
17145718
Cancer Lett. 2007 Jun 8;250(2):250-67
17126996
Eur J Cancer. 1997 Oct;33(12):1997-2001
9516841
Cancer Lett. 2006 Jan 28;232(1):48-57
16221525
Cancer Biol Ther. 2004 Mar;3(3):324-5
15020847
Oncogene. 1999 Nov 18;18(48):6684-91
10597274
Cancer Cell. 2005 Apr;7(4):337-50
15837623
Nat Rev Cancer. 2003 Mar;3(3):203-16
12612655
Cytogenet Genome Res. 2007;118(2-4):260-9
18000379
Pediatr Surg Int. 2004 Jan;20(1):33-8
14691637
Cancer Res. 2005 Feb 1;65(3):828-34
15705880
Oncogene. 2005 Aug 25;24(36):5619-28
16044164
J Clin Oncol. 1993 Aug;11(8):1466-77
8336186
Eur J Cancer. 2005 Mar;41(4):635-46
15737569
Genome Biol. 2006;7(9):R84
16989664
FEBS Lett. 2007 May 29;581(13):2490-6
17490655